Scarica l'app Stockscreener
3.65
2.67%
-0.10
Lixte Biotechnology Holdings Inc Borsa (LIXT) Ultime notizie
Should I hold or sell Lixte Biotechnology Holdings Inc. stock in 2025Weekly Investment Summary & Accurate Technical Buy Alerts - ulpravda.ru
How Lixte Biotechnology Holdings Inc. stock compares to growth peers2025 Momentum Check & Target Return Focused Picks - ulpravda.ru
Can Lixte Biotechnology Holdings Inc. (8640) stock ride next bull market cycleQuarterly Market Review & Technical Buy Zone Confirmation - ulpravda.ru
Will Lixte Biotechnology Holdings Inc. (8640) stock beat revenue estimatesFed Meeting & Low Risk Entry Point Tips - ulpravda.ru
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
LIXTE Biotechnology Holdings (LIXT) Expands Ovarian Cancer Trial With MD Anderson and GSK - Yahoo Finance
Lixte Biotechnology Expands Ovarian Cancer Trial with MD Anderson and GSK - citybuzz -
Will Lixte Biotechnology Holdings Inc. stock benefit from infrastructure spending2025 Volume Leaders & AI Driven Stock Reports - ulpravda.ru
Lixte Biotechnology files to sell 5.26M shares of common stock, warrants - MSN
How strong is Lixte Biotechnology Holdings Inc. Equity Warrant stock revenue growth2025 Trade Ideas & Entry Point Strategy Guides - ulpravda.ru
Lixte Biotechnology announces new registered direct offering - MSN
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Expands Ovarian Cancer Trial With MD Anderson and GSK - financial-news.co.uk
Breakout Zone: Why Lixte Biotechnology Holdings Inc. stock is a value investor pickJuly 2025 Weekly Recap & Real-Time Market Sentiment Reports - ulpravda.ru
Can Lixte Biotechnology Holdings Inc. stock continue upward trendEarnings Forecast Updates & High Yield Trading Growth - ulpravda.ru
Lixte Biotechnology Holdings (NASDAQ: LIXT) Announces $4.3M Registered Direct Offering Priced at Market - Digital Journal
LIXTE Biotechnology Advances Novel Cancer Treatment Platform Through Clinical Trials and Strategic Moves - citybuzz -
Lixte Biotechnology Holdings Secures $4.3 Million in Registered Direct Offering to Advance Cancer Drug Development - citybuzz -
About Us | Oil & Gas JournalLIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Is ‘One to Watch’ - FinancialContent
About Us - FinancialContent
Will Lixte Biotechnology Holdings Inc. (8640) stock deliver compounding returns2026 world cup usa national team quarterfinals young talents transition play winner prediction breakdown - ulpravda.ru
Aug Decliners: Why Lixte Biotechnology Holdings Inc. (8640) stock is listed among top recommendationsInsider Buying & Weekly Momentum Stock Picks - moha.gov.vn
Is Lixte Biotechnology Holdings Inc. stock trading at a premium valuation2026 world cup usa national team qualification midfield engines transition play winner prediction preview - ulpravda.ru
What analysts say about Lixte Biotechnology Holdings Inc 8640 stockCandlestick Trading Patterns & High Return Stock Picks - earlytimes.in
What analysts say about SBCWW stockTechnical Breakout Signals & Free Wealth Planning Blueprints - earlytimes.in
Should You Add Aster DM Healthcare Limited Stock to Your Portfolio NowResistance Breakout Alerts & Minimal Capital Growth - earlytimes.in
Lixte Simplifies Capital Structure via Share Exchange Deal - TipRanks
Price Clustering Detected in Anupam Finserv Limited StockLong-Term Investment Plans & Low Risk High Yield - bollywoodhelpline.com
Will Lixte Biotechnology Holdings Inc. stock see insider buyingTake Profit Strategies & Low Entry Investment Portfolio - Bollywood Helpline
LIXTE expands clinical trial for ovarian cancer treatment By Investing.com - Investing.com Australia
Lixte Expands LB-100 Ovarian Cancer Trial Collaboration - TipRanks
Lixte expands LB-100 ovarian cancer trial collaboration - MSN
Key facts: Lixte Biotechnology secures $4.3M funding; expands cancer collaboration - TradingView — Track All Markets
LIXTE expands clinical trial for ovarian cancer treatment - Investing.com
Lixte Biotechnology Holdings expands collaboration with University of Texas MD Anderson Cancer Center & GSK for LB-100 - marketscreener.com
LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial - InvestorNews
Experimental ovarian cancer trial doubles the number of patients it will enroll - Stock Titan
Spartan Capital acts as placement agent in Lixte’s $4.3 million offering - Investing.com Nigeria
Lixte Biotechnology Announces New Registered Direct Offering - TipRanks
Lixte Biotechnology Signs Multiple Material Agreements - TradingView — Track All Markets
Spartan Capital acts as placement agent in Lixte’s $4.3 million offering By Investing.com - Investing.com South Africa
Lixte Biotechnology stock falls after $4.3 million direct offering - Investing.com
Lixte Biotechnology stock falls after $4.3 million direct offering By Investing.com - Investing.com Canada
Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $4.3 Million Registered Direct Offering - The Manila Times
Will Lixte Biotechnology Holdings Inc. stock keep outperforming rivalsJuly 2025 Setups & Advanced Technical Signal Analysis - Улправда
Whale Trades: Is Lixte Biotechnology Holdings Inc. Equity Warrant stock a contrarian buyMarket Growth Report & Entry and Exit Point Strategies - Улправда
Profit Recap: What sentiment indicators say about Lixte Biotechnology Holdings Inc stockJuly 2025 Big Picture & Weekly Consistent Profit Watchlists - moha.gov.vn
Can Lixte Biotechnology Holdings Inc. Equity Warrant stock deliver consistent earnings growthPortfolio Gains Report & Fast Momentum Entry Tips - Улправда
What Wall Street predicts for Lixte Biotechnology Holdings Inc. Equity Warrant stock pricePortfolio Return Report & Daily Profit Maximizing Trade Tips - Улправда
Is Lixte Biotechnology Holdings Inc. Equity Warrant stock a contrarian buyTrade Risk Summary & Weekly Market Pulse Alerts - Улправда
Is Lixte Biotechnology Holdings Inc. stock a buy before product launchesInsider Buying & Expert Approved Trade Ideas - Улправда
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):